News

Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug ...
The Pharma Letter2d
Ono and Jorna jump into research collab on RNA editing
Japan’s Ono Pharmaceutical and privately-held US firm Jorna Therapeutics are ready to go in a research collaboration ...
PR Newswire3d
Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
About Rona Therapeutics Rona Therapeutics is a global leader in nucleic acid therapeutics discovery and development, specializing in the treatment of cardiometabolic and neurological diseases.
Pharmabiz2d
China NMPA approves Rona Therapeutics’ IND application for RN1871, a novel AGT-targeting siRNA drug for hypertension
China NMPA approves Rona Therapeutics’ IND application for RN1871, a novel AGT-targeting siRNA drug for hypertension: Shanghai, China Tuesday, April 22, 2025, 18:00 Hrs [IST] Ro ...
TMCnet3d
Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics
Under the agreement, Jorna will design RNA editing drug sequences using its proprietary protein and RNA generative AI model, which is based on the quantum mechanics-based AI called SkyEngine. Ono will ...
manilatimes4d
Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
Rona Therapeutics is a global leader in nucleic acid therapeutics discovery and development, specializing in the treatment of cardiometabolic and neurological diseases. Rona Therapeutics is committed ...